26 reports of this reaction
2.5% of all CALCIUM SULFATE ANHYDROUS reports
#6 most reported adverse reaction
ARTHRALGIA is the #6 most commonly reported adverse reaction for CALCIUM SULFATE ANHYDROUS, manufactured by DNA Labs, Inc.. There are 26 FDA adverse event reports linking CALCIUM SULFATE ANHYDROUS to ARTHRALGIA. This represents approximately 2.5% of all 1,039 adverse event reports for this drug.
Patients taking CALCIUM SULFATE ANHYDROUS who experience arthralgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARTHRALGIA is a less commonly reported adverse event for CALCIUM SULFATE ANHYDROUS, but still significant enough to appear in the safety profile.
In addition to arthralgia, the following adverse reactions have been reported for CALCIUM SULFATE ANHYDROUS:
The following drugs have also been linked to arthralgia in FDA adverse event reports:
ARTHRALGIA has been reported as an adverse event in 26 FDA reports for CALCIUM SULFATE ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARTHRALGIA accounts for approximately 2.5% of all adverse event reports for CALCIUM SULFATE ANHYDROUS, making it a notable side effect.
If you experience arthralgia while taking CALCIUM SULFATE ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.